Most formulas target strength training, packing in stimulants and pump-inducing compounds that don't always translate to what runners need
Retatrutide: Designed to Last One of the newest GLP-1 medications in development is retatrutide , a triple agonist (GLP-1, GIP, and glucagon receptors) designed with an approximate 6-day half-life , thanks to advanced pharmaceutical engineering
Weight of evidence: Overall evidence is Low-Moderate: multiple animal studies and a growing number of small clinical trials suggest benefits across gutbrain signaling, social and behavioral domains, gastrointestinal symptoms, and neurophysiological patterns, yet most human studies rely on caregiver-reported outcomes, lack biomarker integration, and seldom control for diet, comorbidities, or baseline microbiome composition
G.WangZ.ZhuW.et al (2018)
This can contribute to digestive issues, inflammation, and autoimmune conditions like IBS and IBD